Cargando…
Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations
We reviewed the current information available on nevirapine immediate- and extended-release formulations and its role in single-dose and combination antiretroviral therapy. Nevirapine was approved in 1996 and was the first non-nucleoside reverse-transcriptase inhibitor available for the treatment of...
Autores principales: | Ena, Javier, Amador, Concepción, Benito, Conxa, Pasquau, Francisco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501953/ https://www.ncbi.nlm.nih.gov/pubmed/23172991 http://dx.doi.org/10.2147/HIV.S35564 |
Ejemplares similares
-
Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan
por: Lee, Chun-Yuan, et al.
Publicado: (2017) -
Pharmacokinetics of immediate release, extended release, and gastric retentive gabapentin formulations in healthy adults
por: Swearingen, Dennis, et al.
Publicado: (2018) -
Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States
por: Iwanicki, Janetta L., et al.
Publicado: (2016) -
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
por: Yone, Eric W Pefura, et al.
Publicado: (2012) -
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
por: Yoon, Seonghae, et al.
Publicado: (2014)